Thematics Asset Management Has $4.04 Million Position in CVS Health Corporation $CVS

Thematics Asset Management cut its position in CVS Health Corporation (NYSE:CVS) by 12.4% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 58,627 shares of the pharmacy operator’s stock after selling 8,284 shares during the period. Thematics Asset Management’s holdings in CVS Health were worth $4,044,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after buying an additional 2,063,737 shares during the period. Dodge & Cox increased its holdings in shares of CVS Health by 4.8% in the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after acquiring an additional 3,353,223 shares in the last quarter. Geode Capital Management LLC raised its position in shares of CVS Health by 2.4% during the second quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock worth $1,966,083,000 after purchasing an additional 675,824 shares during the period. Invesco Ltd. lifted its holdings in shares of CVS Health by 15.3% during the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after purchasing an additional 3,118,626 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of CVS Health in the 2nd quarter valued at approximately $1,358,698,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Trading Down 1.6%

CVS Health stock opened at $75.52 on Monday. The company has a market cap of $95.87 billion, a price-to-earnings ratio of 198.74, a P/E/G ratio of 0.74 and a beta of 0.48. The firm has a 50-day moving average of $78.75 and a 200-day moving average of $71.35. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.63. CVS Health Corporation has a one year low of $43.56 and a one year high of $85.15.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.24. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. During the same quarter in the prior year, the company posted $1.09 earnings per share. CVS Health’s revenue was up 7.8% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, equities analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were paid a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.5%. The ex-dividend date was Thursday, October 23rd. CVS Health’s dividend payout ratio (DPR) is 700.00%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CVS. Sanford C. Bernstein lifted their price target on shares of CVS Health from $77.00 to $86.00 and gave the company a “market perform” rating in a research note on Thursday. Mizuho boosted their price objective on shares of CVS Health from $76.00 to $88.00 and gave the company an “outperform” rating in a research report on Thursday, October 9th. TD Cowen increased their target price on CVS Health from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, November 3rd. Baird R W upgraded CVS Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Leerink Partners increased their price objective on CVS Health from $86.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $90.95.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.